4D Molecular Therapeutics, Inc. 8-K

What Happened
4D Molecular Therapeutics, Inc. (4DMT) announced its financial results for the year ended December 31, 2025. The company furnished a press release dated March 18, 2026 titled “4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” as part of its Form 8‑K under Item 2.02.

Key Details

• Announcement date: March 18, 2026.
• Reporting period: full year ended December 31, 2025.
• Press release furnished as Exhibit 99.1 to the Form 8‑K.
• Form 8‑K was signed by Kristian Humer, Chief Financial Officer, on behalf of 4DMT.

Why It Matters
This 8‑K signals that 4DMT has provided an update on its financial condition and operating results for 2025 — information investors use to assess recent performance and near‑term prospects. Retail investors should read the furnished press release (and the embedded XBRL cover page) for the detailed revenue, expense, cash position, and operational milestones disclosed by the company.